Guardant Health, Inc. $GH Stock Position Lowered by Fifth Third Bancorp

Fifth Third Bancorp reduced its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 33.6% in the 3rd quarter, Holdings Channel reports. The firm owned 34,469 shares of the company’s stock after selling 17,435 shares during the period. Fifth Third Bancorp’s holdings in Guardant Health were worth $6,148,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Financial Network Wealth Advisors LLC boosted its position in shares of Guardant Health by 17.2% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock valued at $75,000 after purchasing an additional 62 shares during the period. Yousif Capital Management LLC increased its position in Guardant Health by 6.2% during the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock worth $283,000 after buying an additional 93 shares during the period. Allworth Financial LP lifted its stake in Guardant Health by 12.4% in the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after buying an additional 118 shares during the last quarter. GAMMA Investing LLC lifted its stake in Guardant Health by 14.5% in the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after buying an additional 122 shares during the last quarter. Finally, Slow Capital Inc. lifted its stake in Guardant Health by 0.3% in the third quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock valued at $9,397,000 after buying an additional 136 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GH has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. Barclays lifted their target price on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. UBS Group lifted their target price on shares of Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Morgan Stanley upped their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, BTIG Research increased their price target on shares of Guardant Health from $195.00 to $210.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.88.

Check Out Our Latest Analysis on Guardant Health

Insider Activity

In related news, CEO Amirali Talasaz sold 37,500 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the sale, the chief executive officer owned 37,500 shares in the company, valued at $6,343,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Alex Azar, II sold 826 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $144,550.00. Following the completion of the sale, the director owned 825 shares of the company’s stock, valued at approximately $144,375. The trade was a 50.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 53,039 shares of company stock valued at $9,088,877. Company insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

GH stock opened at $144.03 on Tuesday. Guardant Health, Inc. has a one year low of $74.55 and a one year high of $191.05. The stock has a market capitalization of $19.49 billion, a PE ratio of -39.14 and a beta of 1.67. The company has a fifty day moving average of $168.29 and a 200-day moving average of $133.16.

Guardant Health (NASDAQ:GH – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. During the same period in the previous year, the firm earned ($0.74) EPS. The firm’s revenue was up 36.1% on a year-over-year basis. Equities analysts forecast that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Guardant Health Profile

(Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

Further Reading

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.